Immunogenicity Study of S-OIV H1N1 Influenza Vaccine

Human Influenza Clinical Trial

Official title:

Study of Humoral and Cellular Immunogenicity of Split-vaccine to Swine-origin H1N1 Influenza

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01096225
• Other study ID #: Immunity_S-OIV_A/H1N1_vaccine
• Status: Active, not recruiting
• Phase: N/A
• First received: March 29, 2010
• Last updated: April 9, 2010
• Start date: March 2010
• Est. completion date: August 2010

Study information

• Verified date: March 2010
• Source: Chinese Academy of Sciences
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Ethics Committee
• Study type: Observational

Clinical Trial Summary

The primary immunogenicity objective is to assess the antibody response and T-cell response of split-virion inactivated A (H1N1) vaccine. Participants will include up to 20 healthy persons of age 20 and older who have no history of novel influenza H1N1 2009 infection in latest 3 months or novel influenza H1N1 2009 vaccination. This is a randomized study in healthy males and non-pregnant females, aged 20 years and older. All subjects will be stratified into 1 dose group (15mcg per dose), and will receive intramuscular influenza H1N1 vaccine. The H1N1 vaccine will be administered at Day 0 and Day 21. On Day 0, Day 10, Day 21, Day 28, Day 35 and Day 42 after first vaccination (Day 0), the immunogenicity testing will be manipulated. The antibody response of immunogenicity testing will be hemagglutination inhibiting (HAI) on serum. The T-cell response will be interferon-gamma ELISPOT assay and Tetramer staining using PBMCs.

Description:

In 2009, a novel swine-origin influenza A/H1N1 virus was identified as a significant cause of febrile respiratory illnesses in North America. It rapidly spread to many countries around the world, which soon meets the World Health Organization (WHO) criteria for a pandemic. Data from several clinical trails with the split-virion inactivated S-OIV vaccine suggest that the vaccine stimulated strong specific antibody against S-OIV. However, the is no T-cell response data after the vaccination. In addition, we do not know S-OIV specific cellular immunity level of the population. These facts indicate the need to assess both the antibody response and T-cell response after the vaccination of the split-virion inactivated S-OIV vaccine. The primary immunogenicity objective is to assess the antibody response and T-cell response of split-virion inactivated A (H1N1) vaccine. Participants will contain only one age group, including up to 20 healthy persons of age 20 and older who have no history of novel influenza H1N1 2009 infection in latest 3 months or novel influenza H1N1 2009 vaccination. This is a randomized study in healthy males and non-pregnant females. All subjects will be stratified into 1 dose group (15mcg per dose), and will receive intramuscular influenza H1N1 vaccine. The H1N1 vaccine will be administered at Day 0 and Day 21. On Day 0, Day 10, Day 21, Day 28, Day 35 and Day 42 after first vaccination (Day 0), the immunogenicity testing will be manipulated. The antibody response of immunogenicity testing will be hemagglutination inhibiting (HAI) on serum. The T-cell response will be interferon-gamma ELISPOT assay and Tetramer staining using PBMCs.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 20
• Est. completion date: August 2010
• Est. primary completion date: April 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 20 Years to 50 Years

Eligibility

Inclusion Criteria:

1. Healthy male or female aged 20 and older

2. Be able to show legal identity card for the sake of recruitment

3. Volunteers or their guardians are able to understand and sign the informed consent

Exclusion Criteria:

1. Cases, cured cases and close contact of influenza A (H1N1) virus

2. Women of pregnancy, lactation or about to be pregnant in 60 days

3. Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine, such as egg, egg protein, etc

4. Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain

5. Autoimmune disease or immunodeficiency

6. Asthma that is unstable or required emergent care, hospitalization or intubation during the past two years or that required the use of oral or intravenous corticosteroids

7. Diabetes mellitus (type I or II), with the exception of gestational diabetes

8. History of thyroidectomy or thyroid disease that required medication within the past 12 months

9. Serious angioedema episodes within the previous 3 years or requiring medication in the previous two years

10. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws

11. Active malignancy or treated malignancy for which there is not reasonable assurance of sustained cure or malignancy that is likely to recur during the period of study

12. Seizure disorder other than:

• Febrile seizures under the age of two years old

• Seizures secondary to alcohol withdrawal more than 3 years ago, or

• A singular seizure not requiring treatment within the last 3 years

13. Asplenia, functional asplenia or any condition resulting in the absence or removal of the spleen

14. Guillain-Barre Syndrome

15. Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)

16. History of any blood products or swine-origin H1N1 or seasonal influenza vaccine administration within 3 months before the dosing

17. Administration of any other investigational research agents within 30 days before the dosing

18. Administration of any live attenuated vaccine within 30 days before the dosing

19. Administration of subunit or inactivated vaccines, e.g., pneumococcal vaccine, or allergy treatment with antigen injections, within 14 days before the dosing

20. Be receiving anti-TB prophylaxis or therapy currently

21. Axillary temperature > 37.0 centigrade at the time of dosing

22. Psychiatric condition that precludes compliance with the protocol:

• Past or present psychoses

• Past or present bipolar disorder requiring therapy that has not been well controlled on medication for the past two years

• Disorder requiring lithium

• Suicidal ideation occurring within five years prior to enrollment

23. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Human Influenza
• Influenza, Human

Intervention

Biological:
• split-virion, H1N1 vaccine of 15 µg
split-virion inactivated S-OIV vaccine of 15 µg on day 0 and 21.

Locations

Country	Name	City	State
China	Institute of microbiology, Chinese Academy of Sciences	Beijing	Beijing

Sponsors (3)

Lead Sponsor	Collaborator
Chinese Academy of Sciences	Hualan Biological Bacterin Co. Ltd, Jiangsu Province Centers for Disease Control and Prevention

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assess the immunity level of the subjects before vaccination.	hemagglutination inhibiting (HAI), ELISPOT and Tetramer staining.	On Day 0 after first vaccination	Yes
Secondary	Assess the immunity level of the subjects 10 days after vaccination	hemagglutination inhibiting (HAI), ELISPOT and Tetramer staining.	On Day 10 after first vaccination	Yes
Secondary	Assess the immunity level of the subjects 21 days after vaccination	hemagglutination inhibiting (HAI), ELISPOT and Tetramer staining.	On Day 21 after first vaccination	Yes
Secondary	Assess the immunity level of the subjects 28 days after vaccination	hemagglutination inhibiting (HAI), ELISPOT and Tetramer staining.	On Day 28 after first vaccination	Yes
Secondary	Assess the immunity level of the subjects 35 days after vaccination	hemagglutination inhibiting (HAI), ELISPOT and Tetramer staining.	On Day 35 after first vaccination	Yes
Secondary	Assess the immunity level of the subjects 42 days after vaccination	hemagglutination inhibiting (HAI), ELISPOT and Tetramer staining.	On Day 42 after first vaccination	Yes